Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Phosphatidylinositol 3-Kinase Inhibitors Pipeline to Witness Increased R&D Investment in the Coming Years

The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates in different stages of development.

 

Request to Get the Sample [email protected] https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis/report-sample

 

Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm. These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells. Phosphatidylinositol 3-kinases is categorized on the basis of classes as class I, II and III, on the basis of structure of the PI3K, based on the specificities of the substrate as well as on the basis of lipid end-product’s nature. Bases on structure, Phosphatidylinositol 3-kinases has four different forms PI3K alpha, PI3K beta, PI3K gamma and PI3K delta.

 

Explore Full Report Description [email protected] https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis 

 

In March 2017, Bayer AG presented clinical results of Phosphoinositide 3-kinase (PI3K)-targeting drug candidate Copanlisib in Phase II CHRONOS-1 trial, evaluating patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (iNHL), trial with NCT ID 01660451. The results across all patient groups showed an objective response rate (ORR) of 59.2%, with a 12% complete response (CR) rate and a median duration of response (DOR) of more than 98 weeks, or 687 days (range 0-687).

 

The research found that different companies engaged in manufacturing of PI3K inhibitors are collaborating. One of the collaborations occurred in November 2016 between Verastem, Inc. and Infinity Pharmaceuticals, Inc.

 

The major players for PI3K Inhibitors Pipeline include, but are not limited to, Novartis AG, Genentech, Inc., SignalRX Pharmaceuticals Inc. and others.

 

About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research-based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Tags: Phosphatidylinositol 3-Kinase Inhibitors Pipeline, Phosphatidylinositol 3-Kinase Inhibitors Pipeline Analysis, Phosphatidylinositol 3-Kinase Inhibitors Pipeline Report, PI3K inhibitors pipeline

See Campaign: http://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysi
Contact Information:
+1-888-778-7886

Tags:
, Research Newswire, Press Release, North America, Latin America, Asia, English

image


This post first appeared on ICrowdNewswire -, please read the originial post: here

Share the post

Phosphatidylinositol 3-Kinase Inhibitors Pipeline to Witness Increased R&D Investment in the Coming Years

×

Subscribe to Icrowdnewswire -

Get updates delivered right to your inbox!

Thank you for your subscription

×